Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

Wet AMD

04.06.21

ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Vision

Source: ForeseeHome

03.31.21

Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenava

Source: Outlook Therapeutics

03.18.21

After the American Academy of Ophthalmology’s Urging, Blue Cross Blue Shield Clarifies Eylea Policy

Source: American Academy of Ophthalmology

03.09.21

Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD

Source: Adverum Biotechnologies

03.09.21

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

Source: Graybug Vision

03.08.21

Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

Source: Alteogen

03.02.21

Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMD

Source: Clearside Biomedical

02.23.21

Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trials

Source: Asclepix Therapeutics

02.16.21

Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseases

Source: Kodiak Sciences

02.16.21

Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.